Skip to main content
OpenTrials
Completed

NCT Number: NCT03910231

The Role of Vasopressin Antagonism on Renal Sodium Handling

Vasopressin has primarily been considered to be a water and osmosis regulating hormone that mediates its effects on renal aquaporin channels. Recent data suggest that vasopressin, through its V2 receptor, may also modulate sodium homeostasis. The purpose of this human physiology study was to test whether antagonism of the V2R alters urine sodium excretion in normal healthy volunteers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

About this study

Vasopressin's potential roles in maintaining normal volume homeostasis are expanding. While previous data support the concept that vasopressin's primary role is in mediating water homeostasis, recent data suggest that vasopressin, through its V2 receptor, may also modulate sodium homeostasis. This effect occurs via activation of the epithelial sodium channel (ENaC). These studies document that vasopressin via activation of the V2 receptor, not only reduces free water excretion but also sodium excretion. These data suggest that blocking this receptor under the right circumstances and in the right population may be effective in modulating hypertension in humans: specifically a V2 receptor antagonist may be effective in treating some individuals that have salt-sensitive hypertension. The current proposal will test in normal human subjects the proof of principle of the above stated hypothesis, and to assess the best markers to determine such an effect. It is important to perform studies with strict environmental control in a clinical research center because of the variability of environmental factors that can create confusion in interpreting data (dietary sodium, activity, body posture, diurnal variation, ambient temperature, sleep-wake cycle, etc.).

The overall program objective is to determine if a vasopressin V2 antagonist will be an effective treatment for salt-sensitive hypertension and if so, what subtype. The object of this specific proposal is to determine the effect of a selective V2 antagonist on sodium handling in normal subjects.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • - Blood pressure <130/85 mmHg and >100/50 mmHg
  • Normal laboratory values for (see "Normal Values" table):
  • Complete blood count
  • Serum creatinine, sodium, potassium, glucose, liver enzymes
  • Urinalysis
  • ECG

Exclusion criteria

  • - Alcohol intake >12 oz per week
  • Tobacco or recreational drug use
  • History of coronary disease, diabetes, hypertension, stroke, kidney disease, or illness requiring overnight hospitalization in the past 6 months
  • Any prescription medication or herbal medication use except oral contraceptive or multivitamin
  • Pregnancy or current breastfeeding
  • First degree relative with hypertension, diabetes, stroke, renal or cardiac disease

Treatment and study plan

Tolvaptan Oral Tablet

Drug

Tolvaptan, to block V2R

Primary outcomes

  1. Acute intravenous saline response

    Time frame: 6 hours

    Urine sodium excretion measured in response to saline infusion

Secondary outcomes

  1. Dietary salt response

    Time frame: 6 days

    Cumulative sodium excretion measured in response to dietary salt loading

Sponsors and collaborators

Lead sponsor

Brigham and Women's Hospital

Other

Collaborators

  • Otsuka Pharmaceutical Co., Ltd.

Registry information

Important dates

Study start
2012
Primary completion
2014
Study completion
2015
First posted
Apr 10, 2019
Registry last updated
Apr 10, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.